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Cell morphologyThe mesenchymal mode of cancer cell invasion characterized by active adhesion turnover and a polarized
actin cytoskeleton, is critically regulated by the adaptor protein NEDD9/HEF1/Cas-L. While it is known that
NEDD9 is subject to extensive phosphorylation modiﬁcation, the molecules that determine NEDD9 phos-
phorylation to stimulate adhesion turnover and mesenchymal cell morphologies are currently unknown. Ear-
lier studies have suggested that the serine/threonine phosphatase PP2A regulates interconversion between a
low molecular mass NEDD9 phosphoform and higher molecular mass phosphoforms. However, previous
studies have used chemical inhibitors to block PP2A activity. In the present study we therefore aimed to spe-
ciﬁcally inhibit PP2A activity via siRNA and dominant negative approaches to investigate the effect of PP2A on
interconversion between 115 kDa and 105 kDa NEDD9 and determine the functional consequence of PP2A
activity for NEDD9 function. Strikingly, we ﬁnd that while the phosphatase inhibitor Calyculin A indeed ab-
rogates detachment-induced dephosphorylation of the 115 kDa NEDD9 phosphoform, PP2A depletion does
not inhibit 115 kDa to 105 kDa interconversion. Our data suggest instead that PP2A targets discrete NEDD9
phosphorylation modiﬁcations separate to the events that mediate interconversion between the two
forms. Functionally, PP2A depletion increases NEDD9 mediated cell spreading and mutation of S369 in the
serine-rich region of NEDD9 to aspartate mimics this effect. Importantly, mutation of S369 to alanine abro-
gates the ability of dominant negative PP2A to increase NEDD9-mediated cell spreading. Collectively, our
data reveal that the tumour suppressor PP2A may act via S369 to regulated NEDD9-mediated cell spreading.
Crown Copyright © 2011 Published by Elsevier B.V. All rights reserved.1. Introduction
Individually invading cancer cellsmay switch betweenmesenchymal
and amoeboid invasionmodes, depending on the composition of the sur-
roundingmatrix [1,2]. Themesenchymal invasionmode is characterized
by a polarized actin cytoskeleton and depends on the regulated forma-
tion and disassembly of integrin-based adhesions to the surrounding
extra-cellular matrix [3]. Recent advances have revealed that the adhe-
sion docking protein NEDD9/HEF1/Cas-L is part of a signalling pathway
that stimulates mesenchymal invasion and antagonizes amoeboid inva-
sion [4]. Elevated expression of NEDD9 has been implicated as a metas-
tasis promoter in a variety of tumour types [5]. NEDD9 contains
multiple consensus serine, threonine and tyrosine phosphorylation mo-
tifs and extensive phosphorylation modiﬁcation of the protein suggestsh Unit, Kids Research Institute,
1, Westmead, 2145, Australia.
.
11 Published by Elsevier B.V. All rigthat this is key to NEDD9 function [6]. Potential regulators of NEDD9
phosphorylation status are the PP2A phosphatases [7]. This enzyme
family displays tumour suppressor activity [8] and regulates a variety
of cellular signalling pathways; however the consequence of PP2A ac-
tivity for NEDD9 adhesion-mediated functions has not been reported.
NEDD9 is an adhesion docking protein that forms part of a signal-
ling hub at integrin-mediated adhesion sites [6]. Lacking enzymatic
activity, NEDD9 regulates the formation of signalling complexes via
its protein–protein interaction domains: a Src Homology 3 (SH3) do-
main; followed by an SH2-binding domain that contains at least 17
tyrosine residues that can be phosphorylated in vivo (Phosphosite da-
tabase [9]); a serine-rich region encompassing 27 serine residues
and; a highly-conserved C-terminal domain [10]. Phosphorylation of
serines, threonines and tyrosines in the NEDD9 sequence modulates
NEDD9 interaction with down-stream signalling partners and thus
regulates NEDD9's signalling function.
NEDD9 is frequently reported as a doublet of ~105 kDa and
115 kDa molecular mass by Western blot and more recently a third
intermediary phosphoformwas reported [11]. The relative expression
of the NEDD9 phosphoforms differs between cell lines and tissueshts reserved.
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and serine residues, while the 115 kDa form is additionally phosphor-
ylated on threonine [13–15]. 105 kDa NEDD9 interconverts to
115 kDa NEDD9 in response to integrin-mediated adhesion [14,16].
Following treatments that disrupt either the actin cytoskeleton or ad-
hesion, 115 kDa NEDD9 collapses to form 105 kDa NEDD9. This can be
abrogated by treatment with Okadaic acid and Calyculin A [14,16,17}.
Based on the data obtained using Okadiac acid and Calyculin A—two
natural products with PP2A inhibitory activity—a model has been
proposed whereby cell detachment leads to PP2A activation, which
is then proposed to catalyze the interconversion from 115 kDa to
105 kDa NEDD9 [7]. Moreover, a recent study demonstrated that mu-
tation of S369 in the NEDD9 serine-rich region speciﬁcally abrogated
Okadaic acid-stimulated interconversion between 105 kDa and
115 kDa NEDD9 [11]. This suggests that PP2A may target NEDD9
S369. However, both Okadaic acid and Calyculin A inhibit phospha-
tases in addition to PP2A [14,18]. Thus to speciﬁcally demonstrate
the role of PP2A in the interconversion between 115 kDa and
105 kDa NEDD9, approaches that directly target PP2A are required.
The PP2A holoenzyme exists as a tri-molecular complex of regula-
tory (B), catalytic (C) and scaffolding (A) subunits and multiple iso-
forms of each subunit provides alternative substrate speciﬁcities
and sub-cellular distributions. An extensive body of work now pro-
vides signiﬁcant support for the notion that PP2A phosphatases
have tumour suppressor activity and it is emerging that one of the
functions of this protein may be to suppress cell migration. Inhibition
of PP2A activity via mutation in a regulatory B subunit stimulated
rapid and extensive cell spreading and the switch to a polarized cyto-
skeleton characteristic of the mesenchymal morphology [19], while
siRNA-mediated targeting of the PP2A catalytic subunit enhanced
cell migration [20]. Notably, NEDD9 overexpression also promotes
cell spreading [12,16,21,22] and leads to a mesenchymal pattern of
actin rearrangement [21]. This switch to mesenchymal invasion is
characterized by a polarized actin cytoskeleton in which a short
mesh work of actin ﬁlaments is localized to the protruding edge and
behind the leading edge discrete actin ﬁlament populations are
arrayed perpendicular (dorsal arcs) and parallel (transverse arcs) to
the leading edge [3]. Thus inhibition of PP2A activity and increased
NEDD9 expression stimulate similar cellular phenotypes, suggesting
the possibility that PP2A may suppress NEDD9-mediated spreading
and inhibit the switch to a mesenchymal phenotype.
The aim of the present study was to compare the effects of Calycu-
lin A treatment versus PP2A knock-down on the interconversion
between 115 kDa and 105 kDa NEDD9 and investigate the
functional consequence of PP2A activity for NEDD9 function. Our
data suggest that PP2A does not regulate the interconversion
between 115 kDa and 105 kDa NEDD9 but instead targets discrete
NEDD9 phosphorylation modiﬁcations separate to those that
mediate interconversion. We show that PP2A suppresses NEDD9
mediated cell spreading and demonstrate a requirement for NEDD9
S369 in this process.
2. Materials and methods
2.1. Antibodies and reagents
Monoclonal antibodies to NEDD9 (clone 2G9) were from ImmuQuest
(Cleveland, UK), monoclonal anti-tubulin and puriﬁed mouse IgG were
purchased from Sigma (Missouri, USA) and phospho-speciﬁc anti-PP2A-
C Y307monoclonal antibodieswere fromEpitomics (California, USA). An-
tibodies against PP2A-C (clone 1D6)were fromUpstate (California, USA).
Secondary HRP-conjugated anti-mouse and anti-rabbit antibodies were
from Amersham (New Jersey, USA) and Biorad (California, USA) and
4′,6-diamidino-2-phenylindole (DAPI) was from Sigma. Cy3-tagged
anti-phalloidinwaspurchased fromSigmaand reconstituted inmethanol.
Calyculin (Chemicon, California, USA) was resuspended in DMSO andMG132 was purchased from Calbiochem (CA, USA). SiGENOME pooled
siRNAs directed against the PP2A subunit and non-targeting siRNA pool
#1 were purchased from Dharmacon (Colorado, USA) and reconstituted
in RNAse free water.
2.2. Creation of GST-fusion peptides and expression plasmids with site-
speciﬁc mutations
Expression plasmids encoding NEDD9 fused with GFP have been
previously described ([16]. The GST.SRR expression construct was pre-
pared by inserting cDNA coding for NEDD9 amino acids 351–653 into
EcoR1–XhoI cloning sites of the pET-41a(+)vector (Novagen). Site spe-
ciﬁc mutation of Serine 369 to either alanine (S369A) or aspartate
(S369D)was achieved using a PCR-basedmutagenesis as previously de-
scribed [23] using GFP.NEDD9 as the template. Primers for mutagenesis
were as follows: S369A (forward: 5′GGATGGGATCAACC-
GATTGGCTTTCTCCAGTACAGGCAGCAC3′, reverse: 5′
GTGCTGCCTGTACTGGAGAAAGCCAATCGGTTGATCCCATCC3′) and
S369D (forward: 5′GGATGGGATCAACCGATTGGATTTCTCCAGTACAGG-
CAGCAC3′, reverse 5′GTGCTGCCTGTACTGGAGAAATCCAATCGGTT-
GATCCCATCC3′). Details of the dominant negative PP2A catalytic
subunit (PP2Ac-L199P) have been previously reported [24].
2.3. Cell culture
MCF-7 cells were maintained in Dulbecco's Modiﬁed Eagles Medi-
um (DMEM, Invitrogen, Victoria, Australia) supplemented with 10%
FBS (Invitrogen) at 37 °C with 5% CO2. For all experiments, cells
were cultured in phenol-red free DMEM plus 10% charcoal treated
FBS supplemented with 10 nM estradiol for at least 7 days prior to
the experiment. Development of the tetracycline-regulatable MCF-7
line was previously described [21]. NEDD9 expression was induced
by culturing cells in the absence of tetracycline for 16–24 h.
2.4. RNA interference
For siRNA knock-down cells (7×105) were plated in 35 mm tissue
culture dishes and incubated overnight. Transfections were per-
formed using RNAiMax (Invitrogen) according to the manufacturer's
instructions. Brieﬂy, RNAiMaxor and 3 pmol of siRNA were incubated
to form complexes in Opti-Mem for 20 min and cells then incubated
with RNAiMaxor-RNA solution for 6 h. Transfections were repeated
in the same cells 24 h later to achieve robust knock-down and cells
were collected for analysis 72 h post -initial transfection.
2.5. Phosphorylation kinetics
Cell quiescence was achieved as described previously [7]. Brieﬂy,
24 h post -ﬁnal siRNA transfection, culture media was changed to
serum-free DMEM with 0.1% heat inactivated bovine serum albumin
(hiBSA). Cells were then rinsed with PBS and detached by incubation
with 3 mM EDTA at 37 °C for 15 min. Following resuspension in
hiBSA, cells were held in suspension by plating into bacterial Petri dishes
for the required time. The zero time point represents cells following de-
tachment with 3 mM EDTA prior to resuspension in hiBSA. For all time
points ﬂoating cells were collected, washed in PBS and extracted in PTY
lysis buffer as normal.
2.6. Co-immunoprecipitation and GST pull-downs
For co-immunoprecipitation analysis, cells were washed twice with
ice-cold PBS and incubated in lysis buffer (10 mM Tris–HCl pH 7.5,
5 mM EDTA pH 8.0, 50 mM sodium ﬂuoride, 10 mM dithiothreitol,
2 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl ﬂuoride,
1% nonidet P-40 (NP-40), 0.05% SDS, 0.25% sodium deoxycholate,
10 μg/ml leupeptin, 10 μg/ml aprotinin) at 4 °C for 30 min. Lysates
Fig. 1. PP2A does not regulate 105 kDa to 115 kDa NEDD9 interconversion. A. Western
blot detection of NEDD9 expression in lysates from attached MCF-7 cells (control), cells
placed in suspension (sus.) or pre-incubated with 10 nM calyculin for 4 h and then
placed in suspension. The histogram shows representative data of the ratio of
115 kDa/105 kDa NEDD9 for each condition, relative to the control sample. B. MCF-7
cells transfected with control siRNA (control) or siRNA targeting PP2A-C, were placed
in suspension (sus.) and incubated for the indicated times (min). The histogram under-
neath shows the ratio of 115 kDa/105 kDa NEDD9 with time, expressed relative to the
level at ‘0’. The heavy signal of the tubulin loading control for the NEDD9 blot reﬂects
the quantity of total protein (75 μg) required in order to visualize NEDD9; tubulin
was not used to normalize protein expression levels. C and D. 115 kDa NEDD9 and
105 kDa expression, respectively, in suspension cultures relative to the zero time
point. Black points show data for cells treated with control siRNA and white points rep-
resent data for cells treated with PP2A-C siRNA. All experiments were repeated in trip-
licate on separate days and the average of three experiments is shown. Error bars show
the SEM. Statistical analysis was performed using two-way ANOVA with Bonferroni
post-tests, *pb0.001, NS=not signiﬁcant.
292 P. Bradbury et al. / Biochimica et Biophysica Acta 1823 (2012) 290–297were brieﬂy centrifuged and supernatants collected. Protein A-
Sepharose (Sigma) was prepared by swelling beads in 10 mM HEPES
buffer, pH 7.2 for 30 min on ice then washing in PBS and resuspending
beads in an equal volume of lysis buffer. Lysates were pre-cleared with
protein A-sepharose for 1 h at 4 °C then collected by centrifugation
(10,000×g) and resulting supernatants incubated with anti-NEDD9,
PP2A-C or isotype-matched, mouse IgG antibodies at 4 °C for 2 h. After
the addition of protein A-Sepharose slurry, incubations were continued
overnight at 4 °C. The resin was collected and washed ﬁve times with
0.5% NP-40 in phosphate-buffered saline then proteins dissociated
from the beads by boiling.
For GST pull-downs, bacterial cells were washed with ice-cold PBS
and incubated in lysis buffer (50 mM HEPES pH 7.4, 150 mM NaCl,
2 mM EDTA, 2 mM sodium ﬂuoride, 2% nonidet P-40 (NP-40), 0.5%
sodium deoxycholate, 0.36 mM sodium orthovanadate, Protease in-
hibitor cocktail (Sigma)) at 4 °C for 10 min. Lysates were brieﬂy cen-
trifuged and supernatants collected. The lysate was pre-cleared of
endogenous GSTs and non-speciﬁcally binding proteins present by in-
cubating with Glutathione Sepharose 4B (GE Healthcare) three times
for 30 min. Pre-cleared lysate (250 μl) was incubated with 20 μl of
1 mg/ml GSH-GST.SRR beads or GSH-recombinant GST (control) beads
at 4 °C for 1 h. Beads were transferred to a Micro Bio-spin column
(BioRad) and washed six times with TBS and four times with 20 mM
Tris, pH 7.4. Proteins bound to the beads were eluted in 1× SDS sample
loading buffer at 85 °C.
2.7. SDS-PAGE and Western blotting
Where indicated, cells were pre-treated with Calyculin A for 4 h.
As the addition of Calyculin A stimulated cell rounding, in all Calycu-
lin treated experiments ﬂoating cells were collected and extracted for
analysis. Protein extractions, equalisation and immunoblotting were
performed as previously described [25]. Proteins were separated by
electrophoresis in 6% acrylamide SDS-polyacrylamide gels to detect
NEDD9 and 12% to detect PP2A-C.
2.8. Imaging and image analysis
Cells grown on coverslips were ﬁxed in 4% paraformaldehyde for
10 min, permeabilised in wash solution (0.2% triton X-100 in 0.5%
BSA) for 5 min then incubated with Cy3 labelled phalloidin diluted
1/1000 in wash solution for 1 h at room temperature. Cells were
then counterstained with DAPI (diluted 1/10,000) for 15 min and cover-
slips mounted onto microscope slides with FluorSave (Calbiochem, San-
Diego, USA). Fluorescent imagingwas performed using anOlympus IX81
invertedmicroscope (Olympus, Pennsylvania, USA) and images captured
by using an ORCA ERG cooled CCD camera (Hamamatsu/SDR Clinical
Technology). Final micrograph images and gray level adjustments were
prepared in Adobe Photoshop. Cell measurements were carried out
usingMetamorph V6.3 software and ﬁnal data analysis in X-cel. Densito-
metric analysis of protein detection onWestern blotswas achieved using
ImageJ 1.34S software (NIH, USA).
3. Results
3.1. PP2A does not regulate the interconversion of 115 kDa to 105 kDa
NEDD9
Detachment from the sub-stratum and treatments that disassemble
the actin cytoskeleton all lead to the loss of 115 kDa NEDD9 [14,16,17]
and blockade of this effect with either Calyculin A or Okadaic acid has
led to the suggestion this is mediated by PP2A activity [7]. That is,
PP2A has been suggested tomediate detachment-induced dephosphor-
ylation of 115 kDa NEDD9 to produce 105 kDa NEDD9. Consistent with
previous observations, treatment with either Calyculin A (Fig. 1A) or
Okadaic acid (data not shown) robustly inhibited suspension-inducedaccumulation of 105 kDaNEDD9. Both 105 kDa and 115 kDaNEDD9 ap-
pear to have reduced electrophoreticmobility in the presence of Calycu-
lin, suggesting that there may be multiple phospho-intermediates of
each form. Moreover, the total levels of NEDD9 are decreased in the
presence of calyculin agreeing with earlier data reporting targeting of
hyper-phosphorylated NEDD9 by the proteasome [7]. These data are
in accord with earlier reports indicating that Calyculin A and Okadaic
acid both block suspension-induced interconversion from 115 kDa
NEDD9 to 105 kDa NEDD9.
We next used siRNA targeting the catalytic subunit of PP2A
(PP2A-C) to establish the role of PP2A in the detachment-induced in-
terconversion of 115 kDa and 105 kDa NEDD9. Knock-down of PP2A
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netic analysis of NEDD9 phosphoforms in suspended cells following
PP2A-C knock-down was performed. Comparison of the effects of
Calyculin A treatment and PP2A depletion revealed striking
differences in NEDD9 regulation (compare Fig. 1A and B). There is
little evidence of 115 kDa NEDD9 accumulation in suspended cells
following PP2A knock-down (Fig. 1B). Moreover, the PP2A-C knock-
down suspended cells retained prominent expression of 105 kDa
NEDD9 (Fig. 1B), in direct contrast to effects seenwith Calyculin A treat-
ment. Analysis of the change in phosphoforms over the 60-minute time
course revealed depletion of 115 kDa NEDD9 and no change in the
levels of 105 kDa NEDD9 in suspended cells following PP2A depletion
(Fig. 1C and D). The differences observed between the effects of Calycu-
lin A and PP2A siRNA therefore suggest that unlike Calyculin A treat-
ment, PP2A depletion does not block the suspension-induced
conversion of 115 kDa to 105 kDa NEDD9. Given that NEDD9 is a highly
phosphorylated protein that contains multiple serine residues, PP2A
may therefore target phosphorylated residues of NEDD9 that are dis-
tinct from those that mediate interconversion between 105 kDa and
115 kDa NEDD9.
3.2. NEDD9 and PP2A interact via the NEDD9 SRR domain
To further investigate the potential interaction between NEDD9
and PP2A we next determined whether NEDD9 interacts with PP2A
in vivo, by performing co-immunoprecipitations from cell lysates.
This revealed that PP2A-C co-immunoprecipitates with anti-NEDD9
antibodies and conversely, that NEDD9 co-immunoprecipitates with
anti-PP2A-C antibodies (Fig. 2A). Notably, both NEDD9 phosphoformsFig. 2. NEDD9 SRR interacts with PP2A. A. Proteins were immunoprecipitated (IP) with the in
induced to express NEDD9. Western blots were probed with the indicated antibodies (W
immunoprecipitating with anti-NEDD9 antibody complexes and (ii) shows NEDD9 co-imm
Schematic representation of NEDD9 protein domains in full length NEDD9 (834 amino aci
Region, CT: C-terminus) and the GST.SRR fusion protein used in GST pull-down experiments
pared from bacteria transformed with the GST.SRR expression construct under control cond
detection of PP2A-C in whole cell lysates (WCL) and following pull-down with glutathionewere observed to co-immunoprecipitate with PP2A and the ratio of
co-immunoprecipitating 105 kDa to 115 kDa NEDD9 (that is, greater
levels of 105 kDa NEDD9) is similar to the ratio of endogenous
NEDD9 in the whole cell lysate (Fig. 2A(ii)). For additional conﬁrma-
tion that NEDD9 forms a complex with PP2A we performed GST-pull-
downs. As it is not possible to express full length NEDD9 in bacteria,
we instead used the NEDD9 serine-rich region (SRR) that has previ-
ously been suggested to have the same tertiary structure as the SRR
domain of the highly related molecule p130Cas [26]. The high level
of serine residues encompassed by the SRR suggested that PP2A
may interact with NEDD9 via this domain, therefore we prepared ex-
pression constructs encoding the SRR domain fused to GST (Fig. 2B
and C). Importantly, pull-downs with the GST.NEDD9.SRR from cell
lysates successfully isolated the catalytic subunit of PP2A (Fig. 2D),
therefore demonstrating that PP2A interacts with the SRR domain of
NEDD9.
3.3. PP2A regulates NEDD9-mediated cell spreading
It is known that elevated NEDD9 expression stimulates cell
spreading [12,21,27] and the adoption of a polarized actin cytoskele-
ton that characterizes the mesenchymal morphology [3,21]. There-
fore, we next measured the effect of PP2A knock-down on NEDD9-
mediated cell spreading and morphologies, following NEDD9 induc-
tion as previously described [21]. First, we examined the effect of
PP2A-C knock-down on total NEDD9 phosphoforms in the adherent
cells that had been induced to express NEDD9 (Fig. 3A and B). In
the adherent cells, little difference was observed in NEDD9 phospho-
forms subsequent to PP2A-C knock-down (Fig. 3B). By comparison,dicated antibodies (control=isotype-matched antibody control) from extracts of cells
B) and whole cell lysates (WCL) included as controls. (i) demonstrates PP2A-C co-
unoprecipitating with anti-PP2A-C complexes. *105 kDa NEDD9, **115 kDa NEDD9. B.
ds) (SH3: Src Homology 3, SH2BD: Src Homology 2 Binding Domain, SRR: Serine Rich
. C. Coomassie stained gel showing the induction of GST.SRR. Protein extracts were pre-
itions (control) or following induction of the fusion protein (induced). D. Western blot
beads coupled to GST control and with the GST.SRR fusion protein.
Fig. 3. PP2A-C knock-down promotes NEDD9-mediated cell spreading. A. Western blot
conﬁrming induction of NEDD9. B. NEDD9 and PP2A-C in protein extracts from the in-
ducible NEDD9 expression cells transfected with siRNA targeting the PP2A catalytic
subunit (PP2A-C) or control siRNA. Blots were probed with tubulin to conﬁrm equal
protein loading. Top histogram shows representative data of the ratio of 115 kDa
NEDD9 to 105 kDa NEDD9 under the indicated conditions. The lower histogram
shows the average % PP2A-C protein remaining following siRNA targeting, from 3 inde-
pendent experiments. C. Western blot of lysates from adherent MCF-7 cells under con-
trol conditions or treated with Calyculin A. Duplicate samples are shown. D. Cells
induced to express NEDD9 and transfected with control or PP2A-C targeted siRNA,
ﬁxed and probed with ﬂuorescently-tagged phalloidin to detect ﬁlamentous actin. Ar-
rows indicate typical crescent-shaped cells. 50 μm scale bar. E. Area of cells induced to
express NEDD9 and transfected with control or PP2A-C targeted siRNA. Data represent
the mean of 3 independent experiments (>45 cells measured per experiment).
F. Higher magniﬁcation image (60× objective) of typical crescent-shaped cell from a
culture expressing elevated NEDD9 and transfected with PP2A-C targeted siRNA.
Fluorescently-tagged phalloidin detects the meshwork of short actin ﬁlaments in the
leading edge (M), the transverse arcs (TA) arrayed parallel to the leading edge and
the dorsal stress ﬁbres (D) at right angles to the leading edge. 10 μm scale bar. Histo-
gram indicates the percentage of crescent-shaped cells. Data represent the average of
3 independent experiments. Error bars represent the S.E.M. *pb0.05, Students t-test.
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105 kDa NEDD9 and a smear of high molecular weight isoforms
(Fig. 3C) similar to the pattern seen in suspended cells treated with
Calyculin A (Fig. 1A). Remarkably, knock-down of PP2A-C combined
with induced NEDD9 expression stimulated signiﬁcantly increased
cell spreading when compared with the induction of NEDD9 alone
(Fig. 3D and E). Examination of cell morphologies following PP2A-C
knock-down additionally revealed signiﬁcantly increased crescent-
shaped cells, typiﬁed by polarized distribution of actin ﬁlaments in-
cluding an actin ﬁlament meshwork at the leading edge, transverse
arcs parallel to the leading edge and dorsal stress ﬁbres perpendicular
to the leading edge (Fig. 3F). Thus, these data suggest that PP2A re-
duces NEDD9-mediated effects on cell spreading and mesenchymal
cell morphology.3.4. Increased cell spreading following PP2A depletion and elevated
NEDD9 requires S369
Mutation of NEDD9 serine 369 to alanine abrogates the formation
of higher molecular weight forms of NEDD9 in response to Okadaic
acid treatment [11]. Agreeing with this, we ﬁnd that the S369A muta-
tion also blocks formation of 115 kDa induced by Calyculin A treat-
ment (Fig. 4B). To next determine whether constitutive
phosphorylation of S369 rescues the formation of 115 kDa NEDD9,
we prepared a phospho-mimetic construct in which S369 was mutat-
ed to aspartate (S369D). However, no doublet of S369D mutant pro-
tein was observed, even after longer exposure times of the
autoradiograph (Fig. 4B). Similarly, although treatment with Calyculin
A stimulated increased 115 kDa GFP.NEDD9 expression relative to the
105 kDa form, S369D remained as a single lower molecular mass band
(Fig. 4B). The lack of an S369D doublet does not appear to be due to pro-
teasomal degradation of the upper 115 kDa form, as neither treatment
with MG132 alone nor in combination with Calyculin A stimulated a
prominent doublet of thismutant protein (Fig. 4B). Thus these data sug-
gest that the phospho-mimeticmutation cannot rescue 115 kDaNEDD9
formation.
Importantly, both S369A and S369D were detected at focal adhe-
sions, as seen for the wild-type NEDD9 GFP fusion protein
(GFP.NEDD9) (Fig. 4C). To determine the consequence of the S369
point mutations for cell spreading, we measured cell area following
transfection with each construct compared to empty vector (GFP)
and wild-type NEDD9 (GFP.NEDD9) controls. This revealed that the
S369A mutant protein increased the cell area to the same extent as
seen for cells expressing wild-type GFP.NEDD9 (Fig. 4C). In contrast,
the S369D mutant construct stimulated a striking further increase in
cell area, resulting in cells with signiﬁcantly larger area than either
GFP.NEDD9 or S369A transfectants (Fig. 4C). Together, these data
suggest that although phosphorylation of S369 is not absolutely re-
quired for NEDD-mediated cell spreading, it is sufﬁcient to stimulate
increased cell spreading.
To investigate the relationship between S369 and PP2A activity, we
next employed a PP2A dominant negative expression construct, which
allowed us to examine combinations of PP2A inhibition together with
NEDD9 expression constructs (Fig. 5A–C). Quantiﬁcation of cell areas
revealed that PP2A.DN alone promoted increased MCF-7 cell spreading
(Fig. 5A and C). Agreeing with the earlier data showing that elevated
NEDD9 expression and PP2A siRNA simulated signiﬁcantly increased
cell area (Fig. 3E), combined expression of PP2A.DN and GFP.NEDD9
resulted in cell areas that were signiﬁcantly larger than cells transfected
with either PP2A.DN or GFP.NEDD9 alone (Fig. 5C). Critically, this effect
was lost when S369A was co-expressed with PP2A.DN, as there was no
difference in area between cells expressing PP2A.DN and S369A either
alone or in combination (Fig. 5C). This suggests that the increased cell
area resulting from combined exogenous NEDD9 expression and de-
creased PP2A activity may be mediated by S369.
Fig. 4.Mutation of NEDD9 S369 recapitulates PP2A knock-down effects. A. Schematic representation of NEDD9 protein sequence indicating position of S369. B. Western blot analysis
of MCF-7 cells transfected with the indicated expression constructs. Exogenous GFP-fused NEDD9 protein phosphoforms are indicated. Transfected cells were grown under control
conditions, in the presence of Calyculin A or MG132 alone and in combination. Two different exposure times (short and longer) of autoradiographs are shown to aid in the iden-
tiﬁcation of GFP.NEDD9 phosphoforms. Note that only the lanes with wild-type GFP.NEDD9 display the high molecular mass 115 kDa NEDD9 phosphoform. C. Images of MCF-7 cells
transfected with the indicated expression constructs. Arrows point to GFP fusion proteins localized to focal adhesions. Scale bar 20 μm. D. Average area of GFP positive cells. Data are
calculated from triplicate repeats on separate occasions. Values were compared using one-way ANOVA with Tukey's Multiple Comparison test, *pb0.05, NS=not signiﬁcant.
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The PP2A serine/threonine phosphatases regulate a variety of cel-
lular signalling pathways and disruption of these pathways via loss of
PP2A activity results in cellular transformation [28]. In the present
study, we show that NEDD9 function is regulated by the PP2A class
of tumour suppressor phosphatases. Identiﬁcation of NEDD9 as part
of this tumour suppressor signalling network underscores the impor-
tant role that deregulated NEDD9 function plays in cancer
progression.
This study has investigated the previously proposed model that
PP2A catalyses detachment-induced dephosphorylation of 115 kDa
NEDD9 to produce the 105 kDa NEDD9 [7]. However, using siRNA-
mediated knock-down of PP2A to allow detection of the speciﬁc
PP2A mediated effects, we have shown that PP2A does not catalyse
detachment-induced dephosphorylation of 115 kDa NEDD9. Indeed,
loss of 115 kDa NEDD9 appeared to be more rapid subsequent to
PP2A knock-down. Instead, our data suggest that PP2A is likely to reg-
ulate phosphorylation modiﬁcations of NEDD9 that are discrete from
the events required to interconvert 105 kDa and 115 kDa NEDD9.
Functionally, we have shown that PP2A suppresses NEDD9-
mediated adhesion dynamics that underlie cell spreading and reduces
the NEDD9-mediated switch to mesenchymal morphologies. We have
further established that NEDD9 and PP2A interact in vivo via theNEDD9
SRRdomain.Wepropose that increased levels of NEDD9—either follow-
ing NEDD9 induction, or in invasive cancers with increased NEDD9 ex-
pression [5]—may exceed the PP2A molecules available for interaction,
thus leading to increased cell spreading andmesenchymalmorphology.The combination of elevated NEDD9 and decreased PP2A via either
siRNA-mediated knock-down or expression of dominant negative
PP2Amay therefore further shift this balance, resulting in additional in-
creases inNEDD9-mediated spreading. Given that inhibition of PP2Aac-
tivity alone promotes cell spreading (Fig. 5C) it was possible that PP2A
depletion and NEDD9 may stimulate cell spreading via parallel path-
ways. However, we show thatmutation of NEDD9 S369 to alanine abro-
gates dominant negative PP2A-induced increases in cell spreading.
Therefore, this reveals that NEDD9 and PP2A functionally interact to
regulate cell spreading. Moreover the ﬁnding that the S369D
phospho-mimetic construct mimics the effects of PP2A knock-down,
suggests that the phosphorylation of this residue is critical to NEDD9
function in adhesion dynamics that lead to cell spreading. Notably, as
expression of the S369A mutant protein alone stimulates spreading
equivalent towild-type GFP.NEDD9, there are likely to be other compo-
nents of the NEDD9 sequence in addition to S369 that regulate cell
spreading.
Targeting of PP2A function via dominant negative approaches [19,29]
and siRNA-mediated knock-down (present study) leads to increased cell
spreading. In addition to the interactionwithNEDD9demonstrated in the
present study, PP2A interacts with other adhesion regulators including
beta integrins [30,31], the integrin-adhesion associated protein paxillin
[20] and the NEDD9-related molecule p130Cas [32]. Each of these pro-
teins contributes to the regulation of adhesion dynamics [33] and collec-
tively these data therefore point to a role for PP2A in regulating the
integrin-adhesion dynamics that determine mesenchymal invasion.
Moreover PP2A appears to collaborate with NEDD9 to determine the ex-
tent of cell spreading and adoption of mesenchymal morphology. A role
Fig. 5. Mutation of NEDD9 S369 abrogates spreading induced by dominant negative
PP2A. A. Images of MCF-7 cells transfected with the indicated expression constructs.
Cells in the bottom rowwere co-transfected with plasmid encoding dominant negative
PP2A (PP2A.DN). Scale bar 20 μm. B. Western blot analysis of MCF-7 cells transfected
with the indicated expression constructs. Cells were co-transfected with GFP expres-
sion constructs and either empty vector control (−) or PP2A.DN (+) as indicated.
C. Average area of GFP positive cells. Data are calculated from triplicate repeats on sep-
arate occasions (~50 cells for each condition per experiment). Values were compared
using one-way ANOVA with Tukey's Multiple Comparison test, ***pb0.001, NS=not
signiﬁcant.
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its role as a tumour suppressor. The switch to an invasive,metastatic phe-
notype is one of the key features of tumour progression and an increasing
number of studies have identiﬁedNEDD9as an importantmetastasis pro-
moter in a range of tumour types [5]. Moreover, NEDD9-mediated inva-
sion is stimulated following inactivation of another tumour suppressor
molecule, LKB1 [34]. Together our data suggest that PP2A may serve as
a brake on NEDD9mediated functions in normal cells and that following
cell transformation and PP2A loss, NEDD9promotion ofmesenchymal in-
vasion may be switched on.
The emerging importance of NEDD9 as a regulator of mesenchy-
mal invasion means that this protein is an attractive target for novel
anti-cancer therapies. However, as NEDD9 is a scaffold that mediates
protein–protein interaction, direct targeting of the NEDD9 protein for
therapeutic purpose may be technically challenging. An alternative
approach is to target enzymes such as PP2A that regulate NEDD9.
The PP2A activator molecule, FTY270/ﬁngolimod, has shown great
promise for the treatment of malignancies [35,36]. Activating muta-
tions of the oncogene c-KIT inhibited PP2A and reversal of this with
the PP2A activator FTY270 led to the conclusion that PP2A inhibition
is essential for c-KIT mediated tumorigenesis [36]. Thus it may be rele-
vant that a recent study established that NEDD9 is also a c-KIT target
[37]. In future studies it will be of signiﬁcant interest to determine
whether PP2A activation may also have efﬁcacy against NEDD9-
mediated invasion in vivo.Acknowledgements
This study was supported by NSW Cancer Council project grant RG
09-16 (GO) and the National Health and Medical Research Council
project grant #632515 (GO). JZ is supported by a University of Sydney
Post-graduate Award and AP is supported by a fellowship from the
Oncology Children's Foundation C4 network. The authors also ac-
knowledge excellent assistance from Lauren Bradshaw (University
of Sydney) and Claire Van Der Helm (University of Utrecht).
References
[1] P. Friedl, Prespeciﬁcation and plasticity: shifting mechanisms of cell migration,
Curr. Opin. Cell Biol. 16 (2004) 14–23.
[2] V. Sanz-Moreno, C.J. Marshall, The plasticity of cytoskeletal dynamics underlying
neoplastic cell migration, Curr. Opin. Cell Biol. 22 (2010) 690–696.
[3] G.M. O'Neill, The coordination between actin ﬁlaments and adhesion inmesenchymal
migration, Cell Adh. Migr. 3 (2009) 355–357.
[4] V. Sanz-Moreno,G. Gadea, J. Ahn, H. Paterson, P.Marra, S. Pinner, E. Sahai, C.J.Marshall,
Rac activation and inactivation control plasticity of tumor cell movement, Cell 135
(2008) 510–523.
[5] G.M. O'Neill, S. Seo, I.G. Serebriiskii, S.R. Lessin, E.A. Golemis, A new central scaffold
for metastasis: parsing HEF1/Cas-L/NEDD9, Cancer Res. 67 (2007) 8975–8979.
[6] M. Singh, L. Cowell, S. Seo, G. O'Neill, E. Golemis,Molecular basis for HEF1/NEDD9/Cas-L
action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle, Cell Bio-
chem. Biophys. 48 (2007) 54–72.
[7] M. Zheng, P.J. McKeown-Longo, Cell adhesion regulates Ser/Thr phosphorylation
and proteasomal degradation of HEF1, J. Cell Sci. 119 (2006) 96–103.
[8] D. Perrotti, P. Neviani, Protein phosphatase 2A (PP2A), a drugable tumor suppressor
in Ph1(+) leukemias, Cancer Metastasis Rev. 27 (2008) 159–168.
[9] P.V. Hornbeck, I. Chabra, J.M. Kornhauser, E. Skrzypek, B. Zhang, PhosphoSite: a bioin-
formatics resource dedicated to physiological protein phosphorylation, Proteomics 4
(2004) 1551–1561.
[10] G.M. O'Neill, S.J. Fashena, E.A. Golemis, Integrin signalling: a new Cas(t) of characters
enters the stage, Trends Cell Biol. 10 (2000) 111–119.
[11] V. Hivert, J. Pierre, J. Raingeaud, Phosphorylation of human enhancer of ﬁlamentation
(HEF1) on serine 369 induces its proteasomal degradation, Biochem. Pharmacol. 78
(2009) 1017–1025.
[12] L.N. Bradshaw, J. Zhong, P. Bradbury, M. Mahmassani, J.L. Smith, A.J. Ammit, G.M.
O'Neill, Estradiol stabilizes the 105-kDa phospho-form of the adhesion docking
protein NEDD9 and suppresses NEDD9-dependent cell spreading in breast cancer
cells, Biochim. Biophys. Acta, Mol. Cell Res. 1813 (2011) 340–345.
[13] S.F. Law, Y.Z. Zhang, A.J. Klein-Szanto, E.A. Golemis, Cell cycle-regulated processing of
HEF1 to multiple protein forms differentially targeted to multiple subcellular com-
partments, Mol. Cell. Biol. 18 (1998) 3540–3551.
[14] M. Zheng, P.J. McKeown-Longo, Regulation of HEF1 expression and phosphorylation
by TGF-beta 1 and cell adhesion, J. Biol. Chem. 277 (2002) 39599–39608.
[15] X. Liu, A.E. Elia, S.F. Law, E.A. Golemis, J. Farley, T. Wang, A novel ability of Smad3
to regulate proteasomal degradation of a Cas family member HEF1, EMBO J. 19
(2000) 6759–6769.
[16] G.M. O'Neill, E.A. Golemis, Proteolysis of the docking protein HEF1 and implications
for focal adhesion dynamics, Mol. Cell. Biol. 21 (2001) 5094–5108.
[17] S.D. Bargon, P.W. Gunning, G.M. O'Neill, The Cas family docking protein, HEF1,
promotes the formation of neurite-like membrane extensions, Biochim. Biophys.
Acta 1746 (2005) 143–154.
[18] L. Fabian, J. Troscianczuk, A. Forer, Calyculin A, an enhancer of myosin, speeds up
anaphase chromosome movement, Cell Chromosome 6 (2007) 1.
[19] A. Ito, T.R. Kataoka, M. Watanabe, K. Nishiyama, Y. Mazaki, H. Sabe, Y. Kitamura, H.
Nojima, A truncated isoform of the PP2A B56 subunit promotes cell motility
through paxillin phosphorylation, EMBO J. 19 (2000) 562–571.
[20] L. Xu, X. Deng, Suppression of cancer cell migration and invasion by protein phos-
phatase 2A through dephosphorylation of mu- and m-calpains, J. Biol. Chem. 281
(2006) 35567–35575.
[21] S.J. Fashena, M.B. Einarson, G.M. O'Neill, C. Patriotis, E.A. Golemis, Dissection of
HEF1-dependent functions in motility and transcriptional regulation, J. Cell Sci.
115 (2002) 99–111.
[22] E. Izumchenko,M.K. Singh, O.V. Plotnikova, N. Tikhmyanova, J.L. Little, I.G. Serebriiskii,
S. Seo, M. Kurokawa, B.L. Egleston, A. Klein-Szanto, E.N. Pugacheva, R.R. Hardy, M.
Wolfson, D.C. Connolly, E.A. Golemis, NEDD9 promotes oncogenic signaling in mam-
mary tumor development, Cancer Res. 69 (2009) 7198–7206.
[23] M. Laible, K. Boonrod, Homemade site directed mutagenesis of whole plasmids, J.
Vis. Exp. (2009) e1135.
[24] H.Y. Chang, P.C. Jennings, J. Stewart, N.M. Verrills, K.T. Jones, Essential role of protein
phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by oka-
daic acid, dominant negative protein phosphatase 2A, and FTY720, J. Biol. Chem. 286
(2011) 14705–14712.
[25] L.N. Cowell, J.D. Graham, A.H. Bouton, C.L. Clarke, G.M. O'Neill, Tamoxifen treatment
promotes phosphorylation of the adhesionmolecules, p130Cas/BCAR1, FAK and Src,
via an adhesion-dependent pathway, Oncogene 25 (2006) 7597–7607.
[26] M.K. Singh, D. Dadke, E. Nicolas, I.G. Serebriiskii, S. Apostolou, A. Canutescu, B.L.
Egleston, E.A. Golemis, A novel Cas family member, HEPL, regulates FAK and cell
spreading, Mol. Biol. Cell 19 (2008) 1627–1636.
297P. Bradbury et al. / Biochimica et Biophysica Acta 1823 (2012) 290–297[27] S.F. Law, G.M. O'Neill, S.J. Fashena, M.B. Einarson, E.A. Golemis, The docking protein
HEF1 is an apoptotic mediator at focal adhesion sites, Mol. Cell. Biol. 20 (2000)
5184–5195.
[28] J.M. Sontag, E. Sontag, Regulation of cell adhesion by PP2A and SV40 small tumor anti-
gen: an important link to cell transformation, Cell. Mol. Life Sci. 63 (2006) 2979–2991.
[29] M. Kong, T.V. Bui, D. Ditsworth, J.J. Gruber, D. Goncharov, V.P. Krymskaya, T. Lindsten,
C.B. Thompson, The PP2A-associated protein alpha4 plays a critical role in the regu-
lation of cell spreading and migration, J. Biol. Chem. 282 (2007) 29712–29720.
[30] J. Mulrooney, K. Foley, S. Vineberg, M. Barreuther, L. Grabel, Phosphorylation of
the [beta]1 integrin cytoplasmic domain: toward an understanding of function
and mechanism, Exp. Cell Res. 258 (2000) 332–341.
[31] S.M. Kim, M.S. Kwon, C.S. Park, K.R. Choi, J.S. Chun, J. Ahn, W.K. Song, Modulation
of Thr phosphorylation of integrin beta1 during muscle differentiation, J. Biol.
Chem. 279 (2004) 7082–7090.
[32] N. Yokoyama, W.T. Miller, Protein phosphatase 2A interacts with the Src kinase
substrate p130(CAS), Oncogene 20 (2001) 6057–6065.
[33] D.J. Webb, K. Donais, L.A. Whitmore, S.M. Thomas, C.E. Turner, J.T. Parsons, A.F.
Horwitz, FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion
disassembly, Nat. Cell Biol. 6 (2004) 154–161.[34] H. Ji,M.R. Ramsey,D.N.Hayes, C. Fan, K.McNamara, P. Kozlowski, C. Torrice,M.C.Wu,
T. Shimamura, S.A. Perera, M.C. Liang, D. Cai, G.N. Naumov, L. Bao, C.M. Contreras, D.
Li, L. Chen, J. Krishnamurthy, J. Koivunen, L.R. Chirieac, R.F. Padera, R.T. Bronson, N.I.
Lindeman, D.C. Christiani, X. Lin, G.I. Shapiro, P.A. Janne, B.E. Johnson, M. Meyerson,
D.J. Kwiatkowski, D.H. Castrillon, N. Bardeesy, N.E. Sharpless, K.K. Wong, LKB1 modu-
lates lung cancer differentiation and metastasis, Nature 448 (2007) 807–810.
[35] P. Neviani, R. Santhanam, J.J. Oaks, A.M. Eiring, M. Notari, B.W. Blaser, S. Liu, R. Trotta,
N. Muthusamy, C. Gambacorti-Passerini, B.J. Druker, J. Cortes, G. Marcucci, C.S. Chen,
N.M. Verrills, D.C. Roy, M.A. Caligiuri, C.D. Bloomﬁeld, J.C. Byrd, D. Perrotti, FTY720, a
new alternative for treating blast crisis chronic myelogenous leukemia and Philadel-
phia chromosome-positive acute lymphocytic leukemia, J. Clin. Invest. 117 (2007)
2408–2421.
[36] K.G. Roberts, A.M. Smith, F. McDougall, H. Carpenter, M. Horan, P. Neviani, J.A. Powell,
D. Thomas, M.A. Guthridge, D. Perrotti, A.T. Sim, L.K. Ashman, N.M. Verrills, Essential
requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reac-
tivation as a strategy to treat c-KIT+ cancers, Cancer Res. 70 (2010) 5438–5447.
[37] B. Thao le, H.A. Vu, K. Yasuda, S. Taniguchi, F. Yagasaki, T. Taguchi, T. Watanabe, Y.
Sato, Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal
tumor cells, Cancer Biol. Ther. 8 (2009) 683–688.
